The life sciences research technology developer has received funding in a series A round co-led by corporate investor ABclonal.

Biotech company ABclonal has co-led a RMB200m ($31m) series A round for China-based life sciences research equipment maker Monad, DealStreetAsia reported on Wednesday, citing a company statement. The round was co-led by investment firm Lucion and also featured venture capital fund Wuxi Capital. Co-founded by Zhuhai Nanshan Investment, Monad provides biological instruments and antibody research…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.